Hostname: page-component-76fb5796d-9pm4c Total loading time: 0 Render date: 2024-04-26T13:08:29.703Z Has data issue: false hasContentIssue false

The importance of integrating genetic strain information for managing cases of Shiga toxin-producing E. coli infection

Published online by Cambridge University Press:  09 September 2019

Dirk Werber*
Affiliation:
Surveillance and Epidemiology of Infectious Diseases, State Office for Health and Social Affairs, 10559 Berlin, Germany
Flemming Scheutz
Affiliation:
Department of Bacteria, Parasites and Fungi, The International Centre for Reference and Research on Escherichia and Klebsiella, Statens Serum Institut, DK-2300 Copenhagen S, Denmark
*
Author for correspondence: Dirk Werber, E-mail: Dirk.Werber@lageso.berlin.de
Rights & Permissions [Opens in a new window]

Abstract

Type
Editorial
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © The Author(s) 2019

The public health importance of Shiga toxin-producing Escherichia (E.) coli (STEC), syn. Vero cytotoxin-producing E. coli, stems primarily from its ability to cause severe disease and severe sequelae in humans, such as haemorrhagic colitis or haemolytic uremic syndrome (HUS). HUS is a life-threatening thrombotic microangiopathy leading to acute renal dysfunction approximately 1 week after the onset of diarrhoea [Reference Tarr, Gordon and Chandler1]. Conservatively estimated, human STEC infection leads annually to 3.890 cases of HUS, primarily in children, and 270 cases of end-stage renal disease, worldwide [Reference Majowicz2].

Shiga toxin-producing Escherichia (E.) coli (STEC) is genetically and phylogenetically a very heterogeneous and large group of organisms [Reference Reid3Reference Haugum5]. Consequently, the potential of STEC to cause severe disease in humans varies widely. Their defining feature, Shiga toxins (Stx), are encoded by genes on bacteriophages and come in two main types, Stx1 and Stx2, and at least 12 subtypes; three for Stx1 (Stx1a, Stx1c, Stx1d) and nine for Stx2 (Stx2a-Stx2i). Serological identification of the somatic (O) and flagellar (H) antigen has been the mainstay of differentiating E. coli [Reference Nataro and Kaper6]. Four hundred and seventy STEC serotypes have been reported [Reference Mora7], of which probably more than 100 cause human illness [Reference Johnson, Thorpe and Sears8]. A less well-defined pathogenic subgroup, denoted enterohaemorrhagic E. coli, has been linked to cause haemorrhagic colitis, and also haemolytic uremic syndrome (HUS). STEC of serotype O157:H7 is the most common cause of HUS in most of the world [Reference Tarr, Gordon and Chandler1]. The serotype is an indicator of the genomic content of an STEC. However, serotype – not a virulence factor itself – does not accurately identify strains that have a high potential of causing HUS. For example, even within the virulent STEC serotype O157:H7, genetic lineages exist that are more prone to cause severe disease than others [Reference Manning9, Reference Dallman10]. Likewise, different toxin profiles exist among human clinical isolates of STEC O157 and they are associated with varying probabilities of causing HUS [Reference Dallman10, Reference Soborg11]. In Europe, approximately 40% of STEC isolated from HUS patients belong to serogroups other than O157 [Reference Kuehne12].

It is generally accepted that the genetic make-up of STEC is a pivotal factor for the severity of the clinical course. Thus, the risk of severe illness from STEC infections is best predicted based on the virulence factors identified for a STEC strain. A substantial body of evidence has accumulated that Stx2a [Reference Eklund, Leino and Siitonen13Reference Friedrich16] and Stx2d [Reference Bielaszewska17] are crucial determinants for the development of HUS. For instance, STEC isolated from HUS patients almost invariably produce Stx2a or, albeit less frequently, Stx2d. Furthermore, the Stx2a encoding gene has emerged as an independent risk factor for the development of HUS in multivariable analyses [Reference Dallman10, Reference Brandal14, Reference de Rauw18, Reference Naseer19]. There are certainly other virulence factors associated with HUS-associated STEC, most prominently the eae gene [Reference Brandal14, Reference Persson15, Reference Naseer19Reference Ethelberg21], which can occasionally be absent in STEC, particularly when isolated from adult HUS patients [Reference Bielaszewska17, Reference Frank22]. In addition, some serogroups independently increase the risk of HUS or severe disease, e.g. O157 [Reference Ethelberg21, Reference Werber23], and presumably also O104 [Reference Preußel24]. The identification of a serogroup as an independent risk factor in the multivariable analysis may indicate that additional virulence factors exist that are exclusively or predominantly present in strains of that serogroup.

Person-to-person transmission, also called secondary transmission, accounts for a small fraction (approximately 15%) of all STEC infections [Reference Kintz25]. Prevention of onward transmission is a public health priority due to the potentially severe outcome. In this issue, Veneti et al. present insightful results of a survey on preventive measures for secondary transmission of STEC, conducted in 2016 among member states of the European Union or European Economic Area [Reference Veneti26]. As the survey revealed, all participating countries (14/32) tailored their efforts to groups of infected persons considered to have a higher probability of transmitting STEC, e.g. children aged <5 years who attend kindergarten, or food handler, for which they advise exclusion from institutional settings or work until the microbiological clearance is obtained. Criteria for microbiological clearance varied between countries, indicating, as the authors point out, a lack of evidence-based knowledge of the infectiousness of persons with formed stools in which STEC is present in low or intermittently undetectable concentrations [27]. More importantly, almost two-thirds of participating countries did not differentiate their control measures according to the virulence profile of the infecting STEC. Only in Denmark, subtyping of the Stx encoding genes (stx) was routinely used at the national level to distinguish strains with a high potential of causing HUS from those with a low potential. Since September 2015, follow-up of cases in Denmark is limited to patients infected by an STEC with a high potential of causing HUS, defined as STEC with stx 2a or stx 2d, regardless of the presence of other virulence genes. STEC with a low potential, i.e. those not carrying stx 2a or stx 2d, are excluded from institutions or work only as long as they are symptomatic, sparing the need for microbiological clearance. Recently, Belgium's National Reference Center changed its STEC typing scheme and risk classification based on own risk factor analyses. Analogously, STEC carrying stx 2a or stx 2d are henceforth immediately detected and reported to public health authorities because they are regarded as STEC with a high potential of causing HUS [Reference de Rauw18].

Partly in response to the survey, Norway has revised its guidelines and now differentiates between low-virulent STEC (that also require no case follow-up) and high-virulent STEC. The chosen classification is similar to the one put in place in Denmark, but differs mainly in that the Norwegian guidelines also consider clinical case characteristics in patients infected with stx 1. The authors not only have to be commended for establishing an evidence base for revising their guidelines, they also illustrate the consequences by retrospectively differentiating the 212 clinical isolates (with available stx profile) from cases reported in Norway in 2016 into low- and high-virulent STEC. Accordingly, in 63% of these STEC infections (n = 133), no follow-up was necessary, and in 21% (n = 45), follow-up would have been necessary for precautionary reasons because information on stx-subtype was not available. Likewise, in Denmark, more than 70% of STEC isolated are considered low pathogenic STEC [Reference Scheutz4]. These results reiterate that most STEC isolated from patients have limited pathogenic potential for causing HUS and this should be accounted for in the management of human STEC infections. Clearly, it is disproportionate to exclude children from child caring institutions and thereby possibly also their guardians from work if the child is infected with an STEC of low or even no virulence, especially when considering potentially long shedding durations of STEC. In a systematic review, average STEC excretion periods of several weeks were reported and a median duration of exclusion from childcare facilities of 39.5 days, meaning that almost half of STEC-infected children were excluded for 6 weeks or longer [Reference Matussek28].

In general, the stringency of control measures should be proportional to the risk they are intending to manage. As such, they need to consider not only the likelihood of the event occurring (in this case, the probability of interpersonal transmission), but also the potential severity of the outcome, which as illustrated above, highly depends on strain characteristics. Thus, integrating genetic information of the STEC strain is necessary for risk-adapted case management. But, why is this not done already at the level of primary diagnosis? The practical implementation in the primary diagnostic laboratories is straightforward as the use of culture-independent diagnostic tests for stx involves the purification of DNA, which can easily be subjected to the stx subtyping procedures described by Scheutz et al. [Reference Scheutz29]. This extended typing algorithm requires no additional amount of labour, little, if any, extra cost and immediately provides physicians and public health authorities with a simple, dichotomised virulence assessment based on stx-subtype (a recently proposed categorisation of STEC in food considers further virulence genes and consists of five risk levels [30]). The fact that 87% of EU's National Reference Laboratories can correctly subtype stx 2 exemplifies the feasibility of the testing procedure [31]. In Denmark, half of the primary diagnostic laboratories have already adopted this scheme successfully.

A microbiologically-based risk assessment already at the level of primary diagnosis would have at least two advantages. First, identifying STEC with a high potential of causing HUS should trigger an immediate notification of the physician so that in turn patients or their guardians can be timely and appropriately counselled about enteric precautions, including hygienic advice. A short time interval between diagnosis and public health guidance to families is associated with a reduced risk of secondary household transmission [Reference Tokuda, Yahata and Sunagawa32]. This is plausible because onward transmission in households occurs often early in the course of the disease [Reference Werber33], when high numbers of bacteria are shed (10 000 000–10 000 000 in case of STEC O157:H7 [Reference Ahn, Klein and Tarr34]) in liquid stools, which are more likely to contaminate hands and the environment than formed stools. In addition, transmission frequently occurs from young patients [Reference Werber33, Reference Snedeker35] to their siblings [Reference Tokuda, Yahata and Sunagawa32, Reference Werber33, Reference Snedeker35]. Separating the paediatric patient from its young sibling at the time of microbiological diagnosis may substantially reduce the risk of secondary transmission, thereby reducing the risk of HUS [Reference Werber33]. Such a stringent precautionary measure, however, should be reserved for potentially severe outcomes, which is why early identification of STEC with a high potential of causing HUS is crucial. A second advantage is that immediate knowledge of the low virulence potential of the aetiologic agent would prevent or reduce concerns of patients, their guardians and even of physicians, and unnecessary stringent precautionary measures for fear of severe disease. Veneti et al. speculate that the incidence specifically of low-virulent STEC may increase in the future in Europe by the more widespread use of culture-independent diagnostic tests for Stx or their encoding genes. This can occur, for example, when stx-diagnostic is integrated into a multiplex PCR for unselected screening of enteropathogenic bacteria [Reference Jenssen36]. This further highlights the need for early classifying STEC with respect to their potential of causing HUS.

We believe a classification that focuses on HUS as a clinical endpoint is justified because it is the most feared complication of STEC infection. Apart from that, not each infection with a high-virulent STEC, however defined, leads to severe disease because the clinical course depends not entirely on strain characteristics but also on other factors, such as ingested dose and host susceptibility. For example, patients’ age (young age [Reference Brandal14], but also ⩾75 years of age [Reference de Rauw18]) and the presence of bloody diarrhoea [Reference Ethelberg21] are also risk factors for severe disease. Furthermore, other virulence factors may exist whose consideration, alone or in combination with stx-subtypes, may allow for a more accurate risk classification. In addition, the evolution of E. coli and also of diagnostic methods continues. Taken together, any such classification scheme should be considered temporary and needs to be re-visited regularly.

Conceivably, the use of next generation sequencing (NGS) technologies may provide a more accurate risk classification. NGS technologies have already been applied in public health practice as they provide phylogenetical subtyping information, relevant for detecting and investigating outbreaks. Moreover, they have the potential of replacing multiple traditional workflows, e.g. serotyping, virulence profiling, by combining them into a single efficient workflow [Reference Besser37]. When performing sequencing directly from clinical specimens and integrating this information into public health surveillance systems, this would be a paradigmatic transformation of both primary diagnostics and public health surveillance [Reference Besser37]. In the meantime, forwarding clinical samples to specialised public health laboratories for timely molecular outbreak surveillance remains an important challenge in most countries [Reference Werber38].

References

1.Tarr, PI, Gordon, CA and Chandler, WL (2005) Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365, 10731086.Google Scholar
2.Majowicz, SE et al. (2014) Global incidence of human Shiga toxin-producing Escherichia coli infections and deaths: a systematic review and knowledge synthesis. Foodborne Pathogens Disease 11, 447455.Google Scholar
3.Reid, SD et al. (2000) Parallel evolution of virulence in pathogenic Escherichia coli. Nature 406, 6467.Google Scholar
4.Scheutz, F (2014) Taxonomy meets public health: the case of Shiga toxin-producing Escherichia coli. Microbiol Spectrum 2, EHEC-0019-2013.Google Scholar
5.Haugum, K et al. (2014) Comparative genomics to delineate pathogenic potential in non-O157 Shiga toxin-producing Escherichia coli (STEC) from patients with and without haemolytic uremic syndrome (HUS) in Norway. PLoS ONE 9, e111788.Google Scholar
6.Nataro, JP and Kaper, JB (1998) Diarrheagenic Escherichia coli. Clinical Microbiology Reviews 11, 142201.Google Scholar
7.Mora, A et al. (2011) Characteristics of the Shiga-toxin-producing enteroaggregative Escherichia coli O104: H4 German outbreak strain and of STEC strains isolated in Spain. International Microbiology 14, 121141.Google Scholar
8.Johnson, KE, Thorpe, CM and Sears, CL (2006) The emerging clinical importance of non-O157 Shiga toxin-producing Escherichia coli. Clinical Infectious Diseases 43, 15871595.Google Scholar
9.Manning, SD et al. (2008) Variation in virulence among clades of Escherichia coli O157: H7 associated with disease outbreaks. Proceedings of the National Academy of Sciences of the USA 105, 48684873.Google Scholar
10.Dallman, TJ et al. (2015) Applying phylogenomics to understand the emergence of Shiga-toxin-producing Escherichia coli O157: H7 strains causing severe human disease in the UK. Microbial Genomics 1, e000029.Google Scholar
11.Soborg, B et al. (2013) A verocytotoxin-producing E. coli outbreak with a surprisingly high risk of haemolytic uraemic syndrome, Denmark, September–October 2012. Euro Surveilliance 18, pii=20350.Google Scholar
12.Kuehne, A et al. (2016) Estimating true incidence of O157 and non-O157 Shiga toxin-producing Escherichia coli illness in Germany based on notification data of haemolytic uraemic syndrome. Epidemiology and Infection 144, 33053315.Google Scholar
13.Eklund, M, Leino, K and Siitonen, A (2002) Clinical Escherichia coli strains carrying stx genes: Stx variants and stx-positive virulence profiles. Journal of Clinical Microbiology 40, 45854593.Google Scholar
14.Brandal, LT et al. (2015) Shiga toxin-producing Escherichia coli infections in Norway, 1992–2012: characterization of isolates and identification of risk factors for haemolytic uremic syndrome. BMC Infectious Diseases 15, 324.Google Scholar
15.Persson, S et al. (2007) Subtyping method for Escherichia coli Shiga toxin (verocytotoxin) 2 variants and correlations to clinical manifestations. Journal of Clinical Microbiology 45, 20202024.Google Scholar
16.Friedrich, AW et al. (2002) Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. Journal of Infectious Diseases 185, 7484.Google Scholar
17.Bielaszewska, M et al. (2006) Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome. Clinical Infectious Diseases 43, 11601167.Google Scholar
18.de Rauw, K et al. (2018) Risk determinants for the development of typical haemolytic uremic syndrome in Belgium and proposition of a new virulence typing algorithm for Shiga toxin-producing Escherichia coli. Epidemiology and Infecton 147, 15.Google Scholar
19.Naseer, U et al. (2017) Virulence factors of Shiga toxin-producing Escherichia coli and the risk of developing haemolytic uraemic syndrome in Norway, 1992–2013. European Journal of Clinical Microbiology and Infectious Diseases 36, 16131620.Google Scholar
20.Boerlin, P et al. (1999) Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. Journal of Clinical Microbiology 37, 497503.Google Scholar
21.Ethelberg, S et al. (2004) Virulence factors for hemolytic uremic syndrome, Denmark. Emerging Infectious Dis 10, 842847.Google Scholar
22.Frank, C et al. (2011) Epidemic profile of Shiga-toxin-producing Escherichia coli O104: H4 outbreak in Germany. The New England Journal of Medicine 365, 17711780.Google Scholar
23.Werber, D et al. (2004) Shiga toxin-producing Escherichia coli O157 more frequently cause bloody diarrhea than do non-O157 strains. Journal of Infectious Diseases 189, 13351336, author reply 1336–1337.Google Scholar
24.Preußel, K et al. (2013) Shiga toxin-producing Escherichia coli O157 is more likely to lead to hospitalization and death than non-O157 serogroups – except O104. PLoS ONE 8, e78180.Google Scholar
25.Kintz, E et al. (2017) Transmission pathways for sporadic Shiga-toxin producing E. coli infections: a systematic review and meta-analysis. International Journal of Hygiene and Environmental Health 220, 5767.Google Scholar
26.Veneti, L et al. (2019) Mapping of control measures to prevent secondary transmission of STEC infections in Europe during 2016 and revision of the national guidelines in Norway. Epidemiology and Infection.Google Scholar
27.European Centre for Disease Prevention and Control (2016) Systematic Review on the Incubation and Infectiousness/Shedding Period of Communicable Diseases in Children. Stockholm: ECDC.Google Scholar
28.Matussek, A et al. (2016) Shiga toxin-producing Escherichia coli in diarrheal stool of Swedish children: evaluation of polymerase chain reaction screening and duration of Shiga toxin shedding. Journal of Pediatric Infectious Diseases Society 5, 147151.Google Scholar
29.Scheutz, F et al. (2012) Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature. Journal of Clinical Microbiology 50, 29512963.Google Scholar
30.Food and Agriculture Organization of the United Nations (2018) Shiga Toxin-Producing Escherichia coli (STEC) and Food: Attribution, Characterization, and Monitoring. Rome: Food and Agriculture Organization of the United Nations (Microbiological risk assessment series no. 31).Google Scholar
31.European Centre for Disease Prevention and Control (2019) External Quality Assessment Scheme for Typing of Shiga Toxin-Producing Escherichia coli. Stockholm: European Centre for Disease Prevention and Control.Google Scholar
32.Tokuda, K, Yahata, Y and Sunagawa, T (2016) Prevention of secondary household transmission during Shiga toxin-producing Escherichia coli outbreaks. Epidemiology and Infection 144, 29312939.Google Scholar
33.Werber, D et al. (2008) Preventing household transmission of Shiga toxin-producing Escherichia coli O157 infection: promptly separating siblings might be the key. Clinical Infectious Diseases 46, 11891196.Google Scholar
34.Ahn, CK, Klein, E and Tarr, PI (2008) Isolation of patients acutely infected with Escherichia coli O157: H7: low-tech, highly effective prevention of hemolytic uremic syndrome. Clinical Infectious Diseases 46, 11971199.Google Scholar
35.Snedeker, KG et al. (2009) Primary and secondary cases in Escherichia coli O157 outbreaks: a statistical analysis. BMC Infectious Diseases 9, 144.Google Scholar
36.Jenssen, GR et al. (2019) Implementation of multiplex PCR diagnostics for gastrointestinal pathogens linked to increase of notified Shiga toxin-producing Escherichia coli cases in Norway, 2007–2017. European Journal of Clinical Microbiology and Infectious Diseases 38, 801809.Google Scholar
37.Besser, J et al. (2018) Next-generation sequencing technologies and their application to the study and control of bacterial infections. Clinical Microbiology and Infection 24, 335341.Google Scholar
38.Werber, D et al. (2012) Outbreaks of virulent diarrheagenic Escherichia coli – are we in control? BMC Medicine 10:11.Google Scholar